Some formulations may be available through compounding pharmacies or sold for research purposes, while others may not be approved for clinical use
While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimers disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk, said in a statement
Were here to help you lose fat, not just weight, and more importantly, keep it off
Its growing cardiovascular-outcomes evidence, combined with expanding reimbursement and manufacturing capacity, positions it to capture an estimated 44% share of global obesity GLP-1 sales by 2035